AAOS 2025: Costal Chondrocyte Pellet ACI vs Microfracture for Articular cartilage defect. .
Costal ChondrocyteDerived PelletType Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect: a Randomized Phase 3 Clinical Trial Compared to Microfracture
One hundred four patients with ICRS grade 3 or 4 articular cartilage defects of the knee (2–10 cm² in area, ≤4 cm³ in volume) were randomized to receive CCP-ACI (n=52) or MFx (n=52). The primary outcome of interest was the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score. Secondary outcomes of interest included complete defect repair, tissue integration, signal intensity of repair tissue, and clinical outcomes. Outcomes were assessed at 8, 24, and 48 weeks. Overall, the results of the study revealed significantly greater MOCART scores and structural cartilage repair in the CCP-ACI group at 24 and 48 weeks, although clinical improvements were comparable between groups. These findings suggest that CCP-ACI leads to better structural regeneration than MFx, with similar clinical benefits in the short term.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics